Europe approves monkeypox vaccine


By Dominic Chopping

Bavarian Nordic AS said Monday that its Imvanex smallpox vaccine has been approved for use against monkeypox by the European Commission.

The approval follows last week’s positive opinion by the European Medicines Agency’s Committee for Medicinal Products for Human Use and is valid in all European Union member states as well as in Iceland, Liechtenstein and Norway, it said.

The World Health Organization declared monkeypox a public health emergency of international concern over the weekend.

The company’s Imvanex vaccine is approved for use against monkeypox by the U.S. and Canada, and Bavarian Nordic has signed several contracts with undisclosed countries for the vaccine, resulting in the company raising its full-year guidance six times in two months.

Shares have more than doubled since the monkeypox outbreak began in mid-May.

Write to Dominic Chopping at

This article was originally published by Read the original article here.

Previous articleElon Musk denies alleged affair with Google co-Founder Sergey Brin’s wife as ‘total bs’
Next articleMarket Extra: Bear-market bottom for U.S. stocks? What the pros say as S&P 500 tests 4,000


Please enter your comment!
Please enter your name here